Cipla, leading drug maker, announced the launch of Serroflo, its Salmeterol/Fluticasone MDI, in Germany and Sweden. With this launch, Cipla opens the door for new, highly efficient treatments in the European healthcare market. Serroflo will substantially improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment.

Commenting on the same, Sarabjit Kour Nangra, VP Research, Pharma, Angel Broking, said, ''Cipla has announced launch of Salmeterol/ Fluticasone combination MDI in Germany and Sweden. The said drug is estimated to have a total market size less than USD 100 million. Thus, the development is not significantly accretive to the company's earnings given the market size, it validates its ability to launch substitutable combination Inhalers in regulated markets and also given that several global players have failed towards this. With other MDI combination inhaler launches waiting in the wings along with the DPI, which is even bigger market size, the inhaler opportunity will be a long-term earnings driver for Cipla, both in EU & US markets over the next five years. We remain neutral on the stock.'' 

Ashish Rathi, research analyst, Emkay Global Financial Services, said, ''Cipla launches first combination inhaler Serroflo in two European countries (Germany and Sweden). We believe growth trajectory ahead remains interesting and incremental launches pose upside risks to our numbers. We upgrade to Buy from Accumulate with TP of Rs 671.''

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.